DiseaseINFOPACK: Clostridium difficile - Rest of World/Emerging markets
Published: May 2010
Clostridium difficile (C.diff) infection (CDI) is an important contributor to the overall burden of hospital acquired-infections (HAIs)
and is responsible for elevated morbidity and mortality in individuals > 65yrs, especially those with underlying co-morbidities.
While oral vancomycin and metronidazole have been the mainstay of CDI treatment for many years, commercial manufacturers
are now focusing of newer treatments including new generation antibiotics (Fidaxomicin, OPT-80) and immunological
approaches e.g. passive and active vaccines.
Although information and literature pertaining to CDI is widespread in major Western markets, a lot less is known in large
emerging economies and "Rest of World" markets. Obtaining such knowledge is critical to begin the formulation of a global
market development strategy for newer CDI interventions.
This DiseaseINFOPACK is a comprehensive up-to-date review of current peer-reviewed literature in emerging economies and
"Rest of World" markets extending upon previous VacZine Analytics analyses conducted in China and Western economies. It
gives a comparative view of current C.diff epidemiology across regions and a critical appraisal of current understanding to date.
